CLINICAL LABS & IMMUNODIAGNOSTICS
Diabetes is relentless. At the current growth rate, diabetes threatens to overwhelm global health care systems in the future. The need for innovation and leadership in the prevention and management of diabetes has never been more important.
Our comprehensive diabetes menu offers outstanding quality and accuracy enabling your lab to do more with less and clinicians to make better treatment decisions to improve the patient care.
Our new VITROS® A1c Solution is revolutionizing how your lab can help clinicians treat patients.
Traceable to standardized materials and good correlation with other commercial assays
Optimizes reagent use and decreases waste
Decreases the number of calibration events
No cuvettes to wash, no probes to clean, no risk of sample nor reagent carry-over
Highly specific antibodies and chemistry detection methods
None-to-minimal cross-reactivity and minimal interferences
Break free from the complexities of whole blood A1c testing with our novel enzymatic VITROS® A1c Slides and enhanced VITROS® Enabling Technologies so that you can report A1c results confidently, while increasing productivity and efficiency.
Its multi-layer Dry Slide design delivers exceptional performance that is certified by the National Glycohemoglobin Standardization Program (NGSP) and is free from hemoglobin variant interference* to bring you result peace of mind.
*Up to HbS ≤ 41%, HbC ≤ 36%, HbD ≤ 41%, HbE ≤ 40%
1. D48434 Whole Blood MicroSlide Processing Theory Guide
2. Up to HbS ≤ 41%, HbC ≤ 36%, HbD ≤ 41%, HbE ≤ 40%, HbA2 ≤ 7%, HbF ≤ 15%
3. National Glycohemoglobin Standardization Program. Certified Methods. http://www.ngsp.org/certified.asp
The VITROS Insulin assay has excellent performance to help clinicians understand the cause of a patient’s hypoglycemia or differentiate between type I and type II diabetes. Measuring insulin levels can evaluate the production and resistance.
The VITROS Insulin assay antibody is highly specific for insulin detection, with no cross-reactivity to C-peptide or Proinsulin.* Importantly it has insignificant or no cross-reactivity to insulin analogs commonly used in diabetes treatment.
*Ding, Qian. Performance Comparison of VITROS Immunodiagnostic Products Insulin Assay. Ortho Clinical Diagnostics PR-03149. 2017
C-peptide testing provides a reliable assessment of beta-cell function and aids in differentiating Type I, Type II diabetes and MODY. Differentiating the diabetes type at clinical presentation is challenging and treatment decisions can improve with clear answers.
The VITROS C-Peptide assay uses an antibody highly specific for C-Peptide detection with no significant cross-reactivities to insulin, proinsulin, glucagon, calcitonin or somatostatin.
Health conditions that alter the red blood cell lifespan are not suitable candidates for traditional HbA1c testing methods. Monitoring glycated serum proteins (GSP) provides clinicians with a short-term glycemic view of two to three weeks that can be used with these conditions and can useful in monitoring the effects of changes in diabetes treatment.
The Glycated Serum Protein Assay uses an enzyme that is highly specific to glycated serum proteins. It does not have interference to reducing substances such as vitamins and bilirubins, unlike older colorimetric fructosamine assays.
Please contact Ortho Care® Services at Fill phone # in by Region to learn how to gain access to specific technical information by registering on the Diazyme Laboratories Inc. website.
*MicroTip Partnership Assay. May not be available in all countries.
Imagine going from clutter to clarity and having seamless control of your lab. Our Ortho Care® Services and Informatics gives you the freedom to focus on patient care.
Is it time to change the way you see your lab? Simplify data to unburden you from the disruptions, complexities and distractions that pull your focus away from patient care. See how network insights, open connectivity and quality management can drive the change your lab needs.